Oral pill that mimics gastric bypass for weight loss
Raised to date
$31.3M
of $35.5M offered across 2 Form D filings
Syntis Bio, Inc. is a pioneering biotechnology company focused on transforming oral therapeutics through innovative solutions targeting the small intestine. By leveraging its proprietary SYNT™ platform, the company enhances the absorption and effectiveness of treatments for prevalent and challenging conditions such as obesity, diabetes, and rare diseases.
Syntis Bio stands out with its mussel-inspired polymer chemistry technology that significantly improves drug bioavailability in the gastrointestinal tract.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jul 2, 2025 | Equity | $25M/ $26.5M | Form D |
| Jan 27, 2025 | Equity | $6.3M/ $9M | Form D |
Oral Therapeutic Platform
SYNT-101 is an innovative oral pill designed to adjust the small intestine's role in metabolism, mimicking the effects of gastric bypass surgery to aid in weight loss management.
Built for
Patients with metabolic and digestive health issues
